Atropos Health’s Post

Watch this interview of Atropos Health Chief Medical Officer and co-founder Dr. Saurabh Gombar as he discusses our recent study of Large Language Models (LLM) for healthcare use. The study “Answering Real-World Clinical Questions Using Large Language Model Based Systems” published in arXiv earlier this month, tested ChatRWD™ (Real World Data) and other general purpose LLMs on their ability to answer clinical questions. ChatRWD (currently in beta) is the first application incorporating chat-to-database capability to help healthcare leaders advance and accelerate evidence generation rapidly, saving organizations valuable time, money, and resources. What sets ChatRWD apart is its ability to generate de novo studies to answer complex medical questions which is unlike other large language models that simply summarize published literature. As we navigate the use of Generative AI in healthcare, its becoming clear that training LLMs on existing literature alone will not be sufficient to answer clinical questions. Learn more about ChatRWD and the study in this video hosted by Jessica Hagen at #HIMSSTV. https://hubs.li/Q02Gvyw70 #HIMSS #healthcare #healthIT #HealthTech #Innovation #Research #Trust #Accuracy #ChatRWD #GenerativeAI #AIinhealthcare #HealthcareAI

ChatRWD™ the first application incorporating chat-to-database capability to help healthcare leaders advance and accelerate evidence generation rapidly, saving organizations valuable time, money, and resources is in the news. Following the publication of “Answering Real-World Clinical Questions Using Large Language Model Based Systems” detailing ChatRWD’s superiority over other large language models (LLMs) when it comes to trust, quality, and accuracy (limited hallucinations), the success of the ChatRWD beta program continues. The key advantage of ChatRWD lies in its ability to provide evidence-based answers even when published literature is lacking, making it an invaluable resource for clinicians faced with challenging cases. From guiding treatment decisions for patients with unique medical histories to assisting with complex drug interactions, ChatRWD is proving to be a key technology for rapid and accurate evidence generation. ChatRWD's ability to generate de novo studies to answer complex medical questions is unlike other large language models that simply summarize published literature. Read more about the recent publication and Stanford's "Patient Like Mine" program and use of ChatRWD here: https://hubs.li/Q02Gknfr0 Ashleigh Hollowell, M.S. Dr. Saurabh Gombar Alexander Chin, MD, MBA #StanfordHealth #AtroposHealth #ChatRWD #AIinHealthcare #RealworldEvidence #RWE #InnovationInMedicine #PatientCare #LargeLanguageModels #LLM

Don't miss Principal Data Scientist Rebecca Hyde's session tomorrow!

Join us LIVE at the Amazon Web Services (AWS) Summit New York. Atropos Health CEO and co-founder Dr. Brigham Hyde is speaking on “How Generative AI is transforming Healthcare and Life Sciences.” Session begins at 12:25 PM eastern. Samantha Perrone, AWS Sales Leader – Healthcare is moderating a panel with Dr. Hyde, Imran Qureshi, CTO & Chief Data Science Officer, b.well Connected Health, and Karim Galil, M.D., Co-Founder/CEO at Mendel.ai to discuss how Generative AI is impacting how we approach drug discovery, clinical trials, and patient care in healthcare and life sciences. Watch the live stream: https://hubs.li/Q02G2PGS0 #awssummit #AtroposHealth #GenerativeAI #Healthcare #LifeScience #clinicaltrials #patientcare

Join us tomorrow, July 10, 2024 at the AWS Summit New York. Atropos Health CEO and co-founder Dr. Brigham Hyde is speaking on “How Generative AI is transforming Healthcare and Life Sciences.” Generative AI is unleashing a wave of innovation in healthcare and life sciences, impacting how we approach drug discovery, clinical trials, patient care, and more. Samantha Perrone, Amazon Web Services (AWS) Sales Leader – Healthcare will moderate this panel with Dr. Hyde, Imran Qureshi, CTO & Chief Data Science Officer, b.well Connected Health, and Karim Galil, M.D., Co-Founder/CEO at Mendel.ai. Join to learn how these experts are applying cutting-edge generative AI technologies to tackle major challenges in these vital industries. Generative AI holds immense potential to impact how we approach healthcare. The panelists will share their visions for the future and the hurdles that still need to be overcome. Learn more about the event: https://hubs.li/Q02FXYTb0 #awssummit #AtroposHealth #GenerativeAI #Healthcare #LifeScience #clinicaltrials #patientcare

The latest study on ChatRWD™ beta has shown that it surpasses Big Tech LLMs in physician trust and the ability to provide complete answers with high-quality evidence. The results, published in a preprint on arXiv, highlight ChatRWD's superiority in delivering reliable and accurate real-world evidence for healthcare. LLMs have increasingly been considered as potential sources of evidence, summarizing information from prior literature learned during LLM training. While LLMs have displayed impressive performance in responding to natural language queries in various medical domains, they are prone to hallucinating reference materials or treatment guidelines and may produce “recommendations” that are inappropriate. Atropos Health tested ChatRWD beta, OpenEvidence, and three “out-of-the-box” LLMs (ChatGPT-4, Claude 3 Opus, and Gemini Pro version 1.5) to answer the same clinical questions context of care delivery. Key Findings: ChatRWD beta outperformed other LLMs with a remarkable 94% completion rate. Independent physician reviewers found ChatRWD beta to provide the best answer to 60% of the questions. Read the full paper to see more results at arXiv. Atropos Health's Chief Medical Officer and co-founder, Dr. Saurabh Gombar, emphasized the importance of rigorously measuring and verifying the reliability of AI technologies in healthcare. ChatRWD's ability to generate evidence for both well-studied and novel questions sets it apart. “Built on the core technology GENEVA OS™ (Generative Evidence Acceleration Operating System), ChatRWD is not tied to any single LLM ,” said Neil Sanghavi, President of Atropos Health. “GENEVA OS is deployed locally...and it does not expose any patient-level clinical or claims data to LLMs; the LLMs in ChatRWD are used to create the query and design the study, but GENEVA OS is used to execute the query - without any connection to the LLMs.” The full launch of ChatRWD is on the horizon, promising to democratize access to transparent, reliable, and personalized real-world evidence for all. Read more and sign-up for the ChatRWD beta program at https://hubs.ly/Q02F0Kvk0 #AtroposHealth #ChatRWD #RealWorldEvidence #HealthcareInnovation #AIinMedicine #LLM #LargeLanguageModels

Join us on July 10 at Amazon Web Services (AWS) Summit New York

The Atropos Evidence Network has grown to over 300 million patients, making it the industry's largest federated healthcare data network. We welcome two new partners and new customer Translational Drug Development (TD2) in our efforts to drive the scale of evidence generation needed to enable personalized evidence for everyone. Atropos Health is committed to providing real world evidence for healthcare decision-making. The Atropos Evidence Network operates on GENEVA OS™ (Generative Evidence Acceleration Operating System), a federated model, forming secure, cloud-based connections between healthcare data proprietors and clinical insight seekers across the healthcare ecosystem. De-identified data doesn’t change hands - reducing data security and identity management risks. Forian Inc. provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments. Syndesis Health is the data and technology catalyst to a multi-continent network of healthcare and life sciences organizations. These partners bring extensive, diverse and high-quality datasets to the Atropos Evidence Network. TD2 is a leader in precision oncology, providing innovative services for improved drug development. TD2 will leverage the Atropos Evidence Network to improve patient outcomes, develop protocols, and clinical trial evidence in oncology. This collaboration will accelerate the development of new therapies and bring them to patients with greater precision and speed. Learn more : https://hubs.li/Q02C--dJ0 #AtroposHealth #HealthcareData #AtroposEvidenceNetwork #PrecisionMedicine #RealWorldData #PatientOutcomes #realworldevidence #RWE #RWD

It's essential to demand robust evidence for healthcare decision-making and transparency into the methods that generate that evidence. #AtroposHealth Chief Medical Officer and co-founder Dr. Saurabh Gombar, an expert in the field, recently penned an insightful op-ed in STAT about the dangers of blindly trusting AI and analytic tools in healthcare. He highlights the need for proper statistical methods for evidence generation when it comes to treatment recommendations. It's crucial for tech companies to uphold the same standards of evidence as pharma companies do for #FDA approval. Let's ensure that care recommendations are based on evidence using sound methodology.  #HealthTech #EvidenceBasedMedicine #PatientCare #HealthcareInnovation #MedicalResearch #DataAnalytics #realworldevidence #decisionsupport #healthcareinnovation

New partnership announcement: Atropos Health has partnered with Norstella to expand the Atropos Evidence™ Network and Structured Clinical Trial Intelligence. This collaboration brings together cutting-edge AI technologies with global data to accelerate innovation for life science. With Norstella's extensive reach and Atropos Health's innovative Generative AI platform, GENEVA OS™, healthcare and life science leaders will have access to advanced evidence-generation tools that will enhance access to democratized federated healthcare data and speed to evidence generation and rapid insights. The combined expertise and solution offerings in real-world evidence between Atropos Health and Norstella are paving the way for faster, more efficient clinical research design, feasibility, and recruitment. Atropos Health will leverage Norstella's extensive reach, including companies such as Panalgo, Citeline, Evaluate, MMIT, and The Dedham Group to improve the quality, accuracy, and efficiency of evidence for their customers and accelerate the pathway to increased adoption of the practice of evidence-based medicine. Thanks to Mike Gallup, Kevin McCurry, Alice Jeffers, Dr. Brigham Hyde, and Kris Karson for bringing our teams together. Read more here: https://hubs.li/Q02C2p7y0 #HealthcareInnovation #EvidenceGeneration #ClinicalTrials #AtroposHealth #Norstella #GENEVAOS #AI #LifeSciences #RWE #Realworldevidence